Darzalex Faspro

Janssen Biotech, Inc.🇺🇸 United States

FDA Page

Effective Date: Sep 3, 2026
Approval ID: 4bb241af-4299-4373-8762-2d6709515db0
Products: 1 registered
Version: 33

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use DARZALEX FASPRO safely and effectively. See full prescribing information for DARZALEX FASPRO. DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) injection, for subcutaneous use Initial U.S. Approval: 2020

Quick Stats

Total Products1

Labelers2

Label Sections38

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.